Oscient kept at market outperform by JMP

JMP Securities analyst Adam Cutler reiterated Oscient Pharmaceuticals Corp. at market outperform after the company reported a loss per share of $0.26, versus JMP's estimate of $0.24 and consensus of $0.22. Factive sales of $9.2 million beat the analyst's $8.3 million estimate, as did total revenue of $11.0 million, over JMP's $10.0 million estimate and consensus of $10.8 million. Shares of the Waltham, Mass., biopharmaceutical company were down 15 cents, or 9.26%, at $1.47 on volume of 1,434,207 shares versus the three-month running average of 437,889 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.